FMBA: Colorectal cancer vaccine

History

2024: Vaccine Creation

The Federal Biomedical Agency (FMBA) of Russia has completed a full cycle of clinical trials of an innovative vaccine for the treatment of colorectal cancer, the introduction of which into medical practice is scheduled for 2025. The test results of the new drug became known in December 2024.

According to TASS, the head of the FMBA Veronika Skvortsova confirmed her readiness to start the practical use of the developed vaccine against intestinal carcinoma from 2025.

𝓲

Фото: Freepik

Now we have fully completed studies on colorectal cancer, this is intestinal carcinoma, and we are ready to start using this vaccine in practice in 2025, "she said on the air of the Russia-24 TV channel.

By the end of 2024, FMBA research teams continue research work on the creation of drugs against other forms of cancer. Particular attention is paid to the development of medicines for the treatment of glioblast - malignant brain tumors, as well as melanomas - an aggressive form of skin cancer.

In parallel with the development of a vaccine against colorectal cancer, agency scientists are working on the creation of personalized oncological drugs, the action of which is based on the individual biological code of the patient. The process of creating such drugs involves several stages: decoding the human genome and its tumor, identifying specific mutations that contribute to the formation and growth of the neoplasm.

An important step in the development of personalized drugs is the study of immunogenic components - peptides to which the immune system of a particular patient responds. Based on the obtained data, an individual drug is created that takes into account the characteristics of the patient's body and the characteristics of the tumor.^[1]

Notes